Immuneering Corp financial data

Symbol
IMRX on Nasdaq
Location
245 Main Street, Second Floor, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.13K % +6.79%
Debt-to-equity 13 % -10.8%
Return On Equity -73.5 % +7.19%
Return On Assets -65 % +5.89%
Operating Margin -12.3M % -127560%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 38M USD -84.1%
Weighted Average Number of Shares Outstanding, Basic 39.7M shares +32.9%
Weighted Average Number of Shares Outstanding, Diluted 39.7M shares +32.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Cost of Revenue 0 USD -100%
Research and Development Expense 47.7M USD +5.85%
General and Administrative Expense 16.5M USD -1.6%
Operating Income (Loss) -64.2M USD -3.83%
Net Income (Loss) Attributable to Parent -62.5M USD -7.63%
Earnings Per Share, Basic -1 USD/shares +8.67%
Earnings Per Share, Diluted -1 USD/shares +8.67%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 228M USD +403%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 229M USD +315%
Property, Plant and Equipment, Net 893K USD -25.9%
Operating Lease, Right-of-Use Asset 3.41M USD -8.99%
Goodwill 6.69M USD 0%
Other Assets, Noncurrent 631K USD -51.3%
Assets 241M USD +252%
Accounts Payable, Current 1.6M USD -17.6%
Accrued Liabilities, Current 7.48M USD +62.9%
Liabilities, Current 9.55M USD +37.9%
Operating Lease, Liability, Noncurrent 3.53M USD -9.75%
Liabilities 13.1M USD +20.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -269M USD -30.3%
Stockholders' Equity Attributable to Parent 228M USD +295%
Liabilities and Equity 241M USD +252%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.1M USD +9.11%
Net Cash Provided by (Used in) Financing Activities 13.8M USD +1309%
Net Cash Provided by (Used in) Investing Activities 21.4M USD +12.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -279K USD -104%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 228M USD +403%
Deferred Tax Assets, Valuation Allowance 59M USD +36.3%
Deferred Tax Assets, Gross 59.3M USD +35.9%
Operating Lease, Liability 3.92M USD -7.66%
Depreciation 90.2K USD +17.9%
Payments to Acquire Property, Plant, and Equipment 8.95K USD -76.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -62.5M USD -7.64%
Lessee, Operating Lease, Liability, to be Paid 5.42M USD -11.9%
Property, Plant and Equipment, Gross 2.22M USD +0.94%
Operating Lease, Liability, Current 382K USD +17.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 785K USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 762K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.5M USD -21.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 808K USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 25.3M USD +32.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.14M USD +62.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 833K USD +3%
Operating Lease, Payments 184K USD -4.7%
Additional Paid in Capital 497M USD +88.2%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 29.3K USD 0%
Depreciation, Depletion and Amortization 335K USD -6.87%
Deferred Tax Assets, Net of Valuation Allowance 344K USD -11.6%
Share-based Payment Arrangement, Expense 6.4M USD -0.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%